Substances · Benzodiazepines and thienodiazepines
Bromazolam
- Preferred name
- Bromazolam
- IUPAC name
- 8-bromo-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
- Parent CAS number (reference)
- 71368-80-4
- Molecular formula
- C17H13BrN4
- Molecular weight
- 353.2 g/mol
- InChIKey
- KCEIOBKDDQAYCM-UHFFFAOYSA-N
- PubChem
- CID 12562546
- Source
- PubChem
- Verified synonyms & catalog abbreviations
-
XLI-269 8-Bromo-alprazolam
Matching Listings in This Store's Catalog
Verified Neurochemical & Toxicological Intelligence
Bromazolam
Receptor Telemetry & Mechanism of Action
Non-selective high-affinity PAM across alpha1, alpha2, alpha3, and alpha5 GABA-A receptor subtypes (structurally the 8-bromo analogue of alprazolam).
Biotransformation & Active Metabolites
Hepatic CYP3A4 hydroxylation to alpha-hydroxybromazolam and 4-hydroxybromazolam followed by glucuronidation.
Temporal Pharmacokinetics
GABA-A Positive Allosteric Modulator (8-Bromo-alprazolam) — 1 tablet = 1 mg sits at the light-to-common threshold; compared to Etizolam, Bromazolam is heavier on physical muscle relaxation and sedation and lasts 2–3 hours longer, while remaining significantly more forgiving per mg than Flualprazolam or Clonazolam.
- Onset 20–45 min
- Peak Window 1.5–3 h
- Total Window 6–10 h
- Residual / Half-Life 8–18 h residual sedation
1 tablet = 1 mg sits at the light-to-common threshold; compared to Etizolam, Bromazolam is heavier on physical muscle relaxation and sedation and lasts 2–3 hours longer, while remaining significantly more forgiving per mg than Flualprazolam or Clonazolam.
Quantitative Response Spectrum (Published Literature)
Third-person observational & toxicological brackets reported in scientific and harm-reduction literature — reference telemetry only, never consumption advice.
0.5 mg
Subtle threshold receptor activity (GABA-A Positive Allosteric Modulator (8-Bromo-alprazolam)).
Minimal baseline autonomic shift.
0.5–1 mg
Mild, clear-headed expression of primary class profile.
Light somatic modulation.
1–2 mg
Full characteristic neurochemical and perceptual profile documented in literature.
Moderate somatic relaxation, ataxia, or autonomic tone depending on class.
2–4 mg
Pronounced intensity, cognitive/motor impairment, or deep immersion.
Marked somatic load and heightened adverse-event sensitivity.
4–5+ mg
Amnesia, blackout, acute dysphoria, confusion, or anesthetic dissociation.
High toxicity zone: severe motor loss, cardiovascular strain, or respiratory hazard.
Interaction Matrix & Critical Contraindications
Critical Hazard — Never Combine
Synergistic brainstem respiratory depression causing unconsciousness and fatal respiratory arrest.
Extreme CNS depression, complete anterograde amnesia, loss of airway reflexes, and fatal aspiration.
Elevated Hazard — Avoid
Unpredictable sedation, severe motor ataxia, blackout, and emesis aspiration hazard.
Caution / Receptor Attenuation
CYP3A4 inhibitors prolong plasma half-life; stimulants mask sedation until they wear off.
Structural Isomer & Sibling Comparison
1 tablet = 1 mg sits at the light-to-common threshold; compared to Etizolam, Bromazolam is heavier on physical muscle relaxation and sedation and lasts 2–3 hours longer, while remaining significantly more forgiving per mg than Flualprazolam or Clonazolam.
Physicochemical Stability & Storage
Form: Precision-pressed 1 mg analytical tablets (1 tablet = 1 mg). · Parent molecule soluble in ethanol, propylene glycol, and DMSO; sparingly soluble in water.
Store sealed in a cool, dry, light-protected container away from humidity.
Cross-Tolerance & Dependence Profile
Complete cross-tolerance across all GABA-A benzodiazepines/thienodiazepines. Rapid physical dependence develops with continuous daily exposure; abrupt cessation after prolonged intake can trigger life-threatening rebound seizures and delirium.
Chemical Architecture & Structural Profile
Bromazolam (8-bromo-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine) is a reference compound belonging to the Benzodiazepines and thienodiazepines class, characterized by the molecular formula C17H13BrN4 and a molar mass of 353.2 g/mol. The parent molecule is indexed under CAS registry number 71368-80-4 and in the NCBI PubChem database as CID 12562546 (Standard InChIKey: KCEIOBKDDQAYCM-UHFFFAOYSA-N).
Citations
- PubChem — PubChem (2026-11-12)
Reference Toxicology & Safety Profile
In documented chemical and harm-reduction literature (PubChem / PsychonautWiki, CC BY 4.0), Bromazolam is indexed within the Benzodiazepines and thienodiazepines structural group. Triazolo/thienodiazepine reference compound; carries a high risk of synergistic respiratory depression if combined with opioids, alcohol, or other CNS depressants. Standard laboratory handling precautions—including nitrile gloves, eye protection, and local exhaust ventilation—apply whenever handling the reference material.
Citations
- PubChem — PubChem (2026-11-12)
Analytical Use & Laboratory Notice
This reference sheet provides chemical, analytical, and toxicological provenance only. The material is strictly not for human consumption, diagnostic, or veterinary use. Research-use labelling does not establish legal status in any jurisdiction.
Citations
- EUDA / National Chemical & Controlled Substance Registry (IE) — National Regulatory Authority (IE) (2026-11-12)